 Whitney High
Concepts (371)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 15 | 2020 | 761 | 2.450 |
Why?
| | Melanoma | 13 | 2020 | 651 | 2.390 |
Why?
| | Skin Diseases | 10 | 2013 | 124 | 2.120 |
Why?
| | Dermatology | 5 | 2013 | 86 | 1.400 |
Why?
| | Skin Diseases, Vesiculobullous | 4 | 2011 | 17 | 1.300 |
Why?
| | Immunohistochemistry | 14 | 2020 | 1642 | 1.140 |
Why?
| | Nephrogenic Fibrosing Dermopathy | 6 | 2012 | 8 | 1.060 |
Why?
| | Nevus, Pigmented | 4 | 2020 | 34 | 0.990 |
Why?
| | Gadolinium DTPA | 6 | 2012 | 54 | 0.940 |
Why?
| | Bedbugs | 2 | 2017 | 2 | 0.920 |
Why?
| | Contrast Media | 9 | 2012 | 369 | 0.860 |
Why?
| | Skin | 11 | 2011 | 662 | 0.820 |
Why?
| | Malpractice | 3 | 2013 | 37 | 0.810 |
Why?
| | Lupus Erythematosus, Cutaneous | 3 | 2007 | 6 | 0.770 |
Why?
| | Gadolinium | 4 | 2010 | 79 | 0.770 |
Why?
| | Dermatitis, Allergic Contact | 3 | 2006 | 63 | 0.680 |
Why?
| | Kidney Failure, Chronic | 3 | 2009 | 490 | 0.640 |
Why?
| | Psoriasis | 3 | 2013 | 75 | 0.640 |
Why?
| | Skin Ulcer | 1 | 2018 | 13 | 0.610 |
Why?
| | Seminoma | 1 | 2018 | 17 | 0.600 |
Why?
| | Histiocytosis, Langerhans-Cell | 2 | 2008 | 35 | 0.600 |
Why?
| | Ectoparasitic Infestations | 1 | 2017 | 3 | 0.580 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2018 | 60 | 0.560 |
Why?
| | Dermatitis, Atopic | 3 | 2013 | 310 | 0.560 |
Why?
| | Testicular Neoplasms | 1 | 2018 | 95 | 0.550 |
Why?
| | Erythema | 3 | 2009 | 25 | 0.530 |
Why?
| | Scrotum | 2 | 2018 | 24 | 0.530 |
Why?
| | Nail Diseases | 2 | 2006 | 4 | 0.510 |
Why?
| | Humans | 68 | 2021 | 115741 | 0.500 |
Why?
| | Fibrosis | 6 | 2008 | 457 | 0.490 |
Why?
| | Medicare | 1 | 2020 | 668 | 0.480 |
Why?
| | Neurothekeoma | 1 | 2014 | 4 | 0.460 |
Why?
| | Defensive Medicine | 1 | 2013 | 2 | 0.460 |
Why?
| | Telepathology | 1 | 2013 | 3 | 0.460 |
Why?
| | Licensure | 1 | 2013 | 10 | 0.460 |
Why?
| | Antibodies, Monoclonal | 3 | 2014 | 1265 | 0.460 |
Why?
| | Diagnostic Errors | 2 | 2012 | 151 | 0.460 |
Why?
| | Lupus Erythematosus, Discoid | 2 | 2015 | 7 | 0.390 |
Why?
| | Male | 37 | 2020 | 56050 | 0.390 |
Why?
| | Scabies | 1 | 2011 | 1 | 0.390 |
Why?
| | Elephantiasis | 1 | 2011 | 3 | 0.380 |
Why?
| | Hidradenitis Suppurativa | 1 | 2011 | 9 | 0.380 |
Why?
| | Genital Diseases, Male | 1 | 2011 | 15 | 0.380 |
Why?
| | Ganglion Cysts | 1 | 2011 | 10 | 0.380 |
Why?
| | Acromioclavicular Joint | 1 | 2011 | 11 | 0.380 |
Why?
| | Biopsy | 7 | 2021 | 1056 | 0.360 |
Why?
| | Piperazines | 2 | 2012 | 314 | 0.350 |
Why?
| | Adult | 28 | 2020 | 30789 | 0.340 |
Why?
| | Pyrimidines | 2 | 2012 | 376 | 0.340 |
Why?
| | Insect Bites and Stings | 1 | 2009 | 13 | 0.340 |
Why?
| | Diagnosis, Differential | 9 | 2015 | 1357 | 0.330 |
Why?
| | Cocaine | 2 | 2012 | 153 | 0.330 |
Why?
| | Antineoplastic Agents | 3 | 2010 | 1893 | 0.330 |
Why?
| | Biomarkers, Tumor | 4 | 2020 | 1048 | 0.330 |
Why?
| | Female | 36 | 2020 | 60018 | 0.330 |
Why?
| | Spectrometry, Fluorescence | 1 | 2009 | 158 | 0.330 |
Why?
| | Keratoacanthoma | 1 | 2008 | 2 | 0.320 |
Why?
| | Keratolytic Agents | 1 | 2008 | 5 | 0.320 |
Why?
| | Isotretinoin | 1 | 2008 | 22 | 0.320 |
Why?
| | Syphilis | 2 | 2005 | 26 | 0.310 |
Why?
| | Hypersensitivity, Delayed | 1 | 2008 | 52 | 0.310 |
Why?
| | Pyroglyphidae | 1 | 2008 | 17 | 0.310 |
Why?
| | Pathology, Clinical | 1 | 2008 | 32 | 0.310 |
Why?
| | Middle Aged | 23 | 2020 | 27069 | 0.300 |
Why?
| | Sweet Syndrome | 1 | 2007 | 7 | 0.300 |
Why?
| | Aged | 20 | 2021 | 19294 | 0.300 |
Why?
| | Kidney Diseases | 2 | 2008 | 354 | 0.300 |
Why?
| | Scleroderma, Systemic | 1 | 2008 | 96 | 0.290 |
Why?
| | Alopecia | 2 | 2013 | 28 | 0.280 |
Why?
| | Skin Diseases, Infectious | 1 | 2007 | 16 | 0.280 |
Why?
| | Dermatomyositis | 2 | 2004 | 23 | 0.280 |
Why?
| | Body Piercing | 1 | 2006 | 4 | 0.280 |
Why?
| | Antibodies, Antinuclear | 2 | 2004 | 60 | 0.280 |
Why?
| | Histiocytoma | 1 | 2006 | 2 | 0.280 |
Why?
| | Hemangiopericytoma | 1 | 2006 | 3 | 0.280 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2007 | 29 | 0.280 |
Why?
| | Communicable Diseases, Emerging | 1 | 2007 | 28 | 0.280 |
Why?
| | Epithelioid Cells | 1 | 2006 | 8 | 0.280 |
Why?
| | Granuloma, Pyogenic | 1 | 2006 | 6 | 0.280 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 1 | 2007 | 40 | 0.270 |
Why?
| | Dermatitis, Seborrheic | 1 | 2006 | 4 | 0.270 |
Why?
| | Exanthema | 1 | 2007 | 77 | 0.270 |
Why?
| | Granuloma | 1 | 2006 | 85 | 0.270 |
Why?
| | Titanium | 1 | 2006 | 74 | 0.260 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2007 | 71 | 0.260 |
Why?
| | Hyperkeratosis, Epidermolytic | 1 | 2005 | 20 | 0.260 |
Why?
| | Neoplasm Regression, Spontaneous | 1 | 2005 | 3 | 0.260 |
Why?
| | Genital Diseases, Female | 1 | 2005 | 27 | 0.260 |
Why?
| | Telemedicine | 1 | 2013 | 667 | 0.250 |
Why?
| | Scalp | 1 | 2005 | 29 | 0.250 |
Why?
| | Tacrolimus | 1 | 2006 | 143 | 0.250 |
Why?
| | Ossification, Heterotopic | 1 | 2004 | 14 | 0.240 |
Why?
| | Ear, External | 1 | 2004 | 23 | 0.240 |
Why?
| | Ear Diseases | 1 | 2004 | 13 | 0.240 |
Why?
| | Quinazolines | 1 | 2006 | 241 | 0.240 |
Why?
| | Allergens | 1 | 2008 | 418 | 0.240 |
Why?
| | Tuberculosis, Miliary | 1 | 2004 | 5 | 0.240 |
Why?
| | Tuberculosis, Cutaneous | 1 | 2004 | 4 | 0.240 |
Why?
| | Agave | 1 | 2003 | 1 | 0.230 |
Why?
| | Biopsy, Needle | 5 | 2011 | 183 | 0.230 |
Why?
| | Fibroma | 1 | 2004 | 21 | 0.230 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2010 | 577 | 0.230 |
Why?
| | Protein Kinase Inhibitors | 2 | 2012 | 790 | 0.230 |
Why?
| | Alendronate | 1 | 2003 | 8 | 0.220 |
Why?
| | Tumor Virus Infections | 1 | 2003 | 41 | 0.220 |
Why?
| | Women's Health | 1 | 2005 | 271 | 0.220 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 301 | 0.220 |
Why?
| | Facial Dermatoses | 1 | 2003 | 14 | 0.220 |
Why?
| | Neoplasm Invasiveness | 2 | 2020 | 445 | 0.220 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2004 | 117 | 0.220 |
Why?
| | Hyperpigmentation | 1 | 2003 | 11 | 0.220 |
Why?
| | United States | 7 | 2020 | 12304 | 0.220 |
Why?
| | Vasculitis | 1 | 2003 | 71 | 0.220 |
Why?
| | Papillomaviridae | 1 | 2003 | 100 | 0.210 |
Why?
| | Lymphatic Metastasis | 2 | 2019 | 276 | 0.210 |
Why?
| | Pregnancy Outcome | 1 | 2005 | 337 | 0.210 |
Why?
| | Cicatrix | 1 | 2003 | 50 | 0.210 |
Why?
| | Antirheumatic Agents | 1 | 2005 | 255 | 0.210 |
Why?
| | Prognosis | 5 | 2017 | 3343 | 0.210 |
Why?
| | Cheilitis | 1 | 2021 | 3 | 0.200 |
Why?
| | Patch Tests | 3 | 2008 | 52 | 0.190 |
Why?
| | Pregnancy Complications | 1 | 2005 | 431 | 0.180 |
Why?
| | Cannabis | 1 | 2007 | 385 | 0.180 |
Why?
| | Aged, 80 and over | 8 | 2015 | 6423 | 0.180 |
Why?
| | Genetic Testing | 2 | 2017 | 382 | 0.180 |
Why?
| | Pulmonary Fibrosis | 1 | 2003 | 330 | 0.180 |
Why?
| | MART-1 Antigen | 1 | 2020 | 10 | 0.180 |
Why?
| | Papillomavirus Infections | 1 | 2003 | 258 | 0.180 |
Why?
| | Head and Neck Neoplasms | 2 | 2019 | 425 | 0.180 |
Why?
| | SOXE Transcription Factors | 1 | 2020 | 17 | 0.170 |
Why?
| | Benzamides | 2 | 2012 | 168 | 0.170 |
Why?
| | Societies, Medical | 1 | 2003 | 684 | 0.170 |
Why?
| | HIV Infections | 2 | 2004 | 2474 | 0.170 |
Why?
| | Retrospective Studies | 8 | 2020 | 12633 | 0.170 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 231 | 0.160 |
Why?
| | Methotrexate | 3 | 2012 | 228 | 0.150 |
Why?
| | Dermoscopy | 2 | 2017 | 9 | 0.150 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2019 | 277 | 0.150 |
Why?
| | Comparative Genomic Hybridization | 1 | 2017 | 28 | 0.150 |
Why?
| | STAT3 Transcription Factor | 1 | 2019 | 174 | 0.150 |
Why?
| | Lip | 2 | 2021 | 20 | 0.150 |
Why?
| | Pruritus | 2 | 2009 | 60 | 0.140 |
Why?
| | Severity of Illness Index | 4 | 2009 | 2586 | 0.140 |
Why?
| | Bites and Stings | 1 | 2017 | 30 | 0.140 |
Why?
| | Tumor Suppressor Proteins | 1 | 2019 | 286 | 0.140 |
Why?
| | Risk Assessment | 5 | 2011 | 2990 | 0.140 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2017 | 310 | 0.130 |
Why?
| | Mutation | 1 | 2007 | 3364 | 0.130 |
Why?
| | Dermatologic Agents | 2 | 2013 | 57 | 0.130 |
Why?
| | Lichenoid Eruptions | 1 | 2015 | 3 | 0.130 |
Why?
| | Magnetic Resonance Imaging | 4 | 2011 | 3122 | 0.130 |
Why?
| | Sampling Studies | 2 | 2007 | 95 | 0.130 |
Why?
| | Child, Preschool | 4 | 2014 | 9138 | 0.130 |
Why?
| | Child | 6 | 2014 | 18503 | 0.130 |
Why?
| | Follow-Up Studies | 4 | 2011 | 4442 | 0.120 |
Why?
| | Renal Dialysis | 2 | 2009 | 369 | 0.120 |
Why?
| | Animals | 8 | 2019 | 32104 | 0.120 |
Why?
| | Mass Spectrometry | 2 | 2008 | 645 | 0.120 |
Why?
| | Internship and Residency | 1 | 2003 | 951 | 0.120 |
Why?
| | Face | 1 | 2015 | 167 | 0.120 |
Why?
| | Insurance, Liability | 1 | 2013 | 6 | 0.110 |
Why?
| | Mohs Surgery | 2 | 2004 | 24 | 0.110 |
Why?
| | Gene Expression Profiling | 1 | 2020 | 1537 | 0.110 |
Why?
| | Liability, Legal | 1 | 2013 | 38 | 0.110 |
Why?
| | Photography | 1 | 2013 | 89 | 0.110 |
Why?
| | Immunosuppressive Agents | 2 | 2009 | 666 | 0.100 |
Why?
| | Antinematodal Agents | 1 | 2012 | 5 | 0.100 |
Why?
| | Imatinib Mesylate | 2 | 2012 | 64 | 0.100 |
Why?
| | Fetal Diseases | 1 | 2013 | 148 | 0.100 |
Why?
| | Levamisole | 1 | 2012 | 20 | 0.100 |
Why?
| | Drug Contamination | 1 | 2012 | 53 | 0.100 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2012 | 41 | 0.100 |
Why?
| | Pilot Projects | 2 | 2006 | 1384 | 0.100 |
Why?
| | Carcinoma, Basal Cell | 2 | 2010 | 68 | 0.100 |
Why?
| | Argyria | 1 | 2011 | 4 | 0.100 |
Why?
| | Orphanages | 1 | 2011 | 2 | 0.100 |
Why?
| | Granuloma, Foreign-Body | 1 | 2011 | 10 | 0.100 |
Why?
| | Vietnam | 1 | 2011 | 21 | 0.100 |
Why?
| | Ethiopia | 1 | 2011 | 34 | 0.100 |
Why?
| | Durapatite | 1 | 2011 | 32 | 0.100 |
Why?
| | Synovial Fluid | 1 | 2011 | 57 | 0.100 |
Why?
| | Treatment Outcome | 4 | 2012 | 9162 | 0.090 |
Why?
| | Foreign-Body Migration | 1 | 2011 | 38 | 0.090 |
Why?
| | Sensitivity and Specificity | 3 | 2020 | 1730 | 0.090 |
Why?
| | Adoption | 1 | 2011 | 38 | 0.090 |
Why?
| | Transcription Factors | 1 | 2019 | 1528 | 0.090 |
Why?
| | Cocaine-Related Disorders | 1 | 2012 | 107 | 0.090 |
Why?
| | Rupture | 1 | 2011 | 95 | 0.090 |
Why?
| | Adolescent | 5 | 2014 | 17922 | 0.090 |
Why?
| | Mucins | 1 | 2011 | 61 | 0.090 |
Why?
| | Rotator Cuff Injuries | 1 | 2011 | 54 | 0.090 |
Why?
| | Cell Differentiation | 1 | 2018 | 1700 | 0.090 |
Why?
| | China | 1 | 2011 | 163 | 0.090 |
Why?
| | Practice Guidelines as Topic | 2 | 2008 | 1405 | 0.090 |
Why?
| | Aminolevulinic Acid | 1 | 2010 | 2 | 0.090 |
Why?
| | Health Care Costs | 1 | 2013 | 384 | 0.090 |
Why?
| | Injections, Intralesional | 1 | 2010 | 32 | 0.090 |
Why?
| | Guatemala | 1 | 2011 | 268 | 0.090 |
Why?
| | Algorithms | 1 | 2017 | 1500 | 0.090 |
Why?
| | Eccrine Glands | 1 | 2009 | 2 | 0.090 |
Why?
| | Synchrotrons | 1 | 2009 | 8 | 0.090 |
Why?
| | Photopheresis | 1 | 2009 | 9 | 0.090 |
Why?
| | Iron-Dextran Complex | 1 | 2009 | 10 | 0.090 |
Why?
| | Ultraviolet Therapy | 1 | 2009 | 16 | 0.090 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2010 | 80 | 0.090 |
Why?
| | Plasmapheresis | 1 | 2009 | 22 | 0.090 |
Why?
| | Arthropod Vectors | 1 | 2009 | 7 | 0.080 |
Why?
| | Observation | 1 | 2009 | 50 | 0.080 |
Why?
| | Bedding and Linens | 1 | 2009 | 9 | 0.080 |
Why?
| | Hyaluronic Acid | 1 | 2011 | 190 | 0.080 |
Why?
| | Naphthoquinones | 1 | 2009 | 17 | 0.080 |
Why?
| | Fluorouracil | 1 | 2010 | 151 | 0.080 |
Why?
| | Rituximab | 1 | 2010 | 149 | 0.080 |
Why?
| | Lymphoma, B-Cell | 1 | 2010 | 86 | 0.080 |
Why?
| | Erythropoietin | 1 | 2009 | 72 | 0.080 |
Why?
| | Vitiligo | 1 | 2009 | 52 | 0.080 |
Why?
| | Interferon-alpha | 1 | 2010 | 186 | 0.080 |
Why?
| | Interleukin-2 | 1 | 2010 | 417 | 0.080 |
Why?
| | Bleomycin | 1 | 2010 | 232 | 0.080 |
Why?
| | Histiocytes | 1 | 2008 | 6 | 0.080 |
Why?
| | Histiocytosis | 1 | 2008 | 8 | 0.080 |
Why?
| | Langerhans Cells | 1 | 2008 | 11 | 0.080 |
Why?
| | Diabetes Insipidus | 1 | 2008 | 7 | 0.080 |
Why?
| | Carcinoma, Skin Appendage | 1 | 2007 | 2 | 0.080 |
Why?
| | Failure to Thrive | 1 | 2008 | 32 | 0.080 |
Why?
| | Prednisone | 2 | 2012 | 232 | 0.080 |
Why?
| | Neoplasm Metastasis | 1 | 2010 | 526 | 0.080 |
Why?
| | Microtubule-Associated Proteins | 1 | 2009 | 174 | 0.080 |
Why?
| | Imidazoles | 1 | 2009 | 217 | 0.070 |
Why?
| | Antigen-Presenting Cells | 1 | 2008 | 153 | 0.070 |
Why?
| | Case-Control Studies | 2 | 2020 | 3037 | 0.070 |
Why?
| | Medical Records | 1 | 2008 | 157 | 0.070 |
Why?
| | Pregnancy | 3 | 2013 | 5553 | 0.070 |
Why?
| | Bone Diseases | 1 | 2008 | 58 | 0.070 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2008 | 129 | 0.070 |
Why?
| | Risk Management | 1 | 2008 | 89 | 0.070 |
Why?
| | Keratinocytes | 1 | 2008 | 215 | 0.070 |
Why?
| | Amoeba | 1 | 2007 | 1 | 0.070 |
Why?
| | Gnathostoma | 1 | 2007 | 1 | 0.070 |
Why?
| | Pythium | 1 | 2007 | 1 | 0.070 |
Why?
| | Spirurida Infections | 1 | 2007 | 1 | 0.070 |
Why?
| | Amebiasis | 1 | 2007 | 5 | 0.070 |
Why?
| | Penicillium | 1 | 2007 | 6 | 0.070 |
Why?
| | Skull | 1 | 2008 | 117 | 0.070 |
Why?
| | Genes, p16 | 1 | 2007 | 17 | 0.070 |
Why?
| | Electron Probe Microanalysis | 1 | 2006 | 3 | 0.070 |
Why?
| | Microphthalmia-Associated Transcription Factor | 1 | 2007 | 14 | 0.070 |
Why?
| | Epidermis | 1 | 2007 | 149 | 0.070 |
Why?
| | Receptor, Melanocortin, Type 1 | 1 | 2007 | 23 | 0.070 |
Why?
| | Paraffin Embedding | 1 | 2006 | 21 | 0.070 |
Why?
| | Subcutaneous Tissue | 1 | 2006 | 17 | 0.070 |
Why?
| | Factor XIIIa | 1 | 2006 | 5 | 0.070 |
Why?
| | Diabetic Nephropathies | 1 | 2009 | 234 | 0.070 |
Why?
| | Hypopigmentation | 1 | 2006 | 2 | 0.070 |
Why?
| | Dermis | 1 | 2006 | 30 | 0.070 |
Why?
| | Combined Modality Therapy | 1 | 2009 | 1127 | 0.070 |
Why?
| | Dosage Forms | 1 | 2006 | 10 | 0.070 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2006 | 12 | 0.070 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2006 | 194 | 0.070 |
Why?
| | Signal Transduction | 1 | 2019 | 4541 | 0.070 |
Why?
| | Lysosomes | 1 | 2006 | 125 | 0.070 |
Why?
| | Organ Specificity | 1 | 2006 | 273 | 0.070 |
Why?
| | Single-Blind Method | 1 | 2006 | 255 | 0.070 |
Why?
| | Metals | 1 | 2006 | 109 | 0.070 |
Why?
| | Tissue Distribution | 1 | 2006 | 324 | 0.060 |
Why?
| | PTEN Phosphohydrolase | 1 | 2007 | 142 | 0.060 |
Why?
| | Acidosis | 1 | 2006 | 87 | 0.060 |
Why?
| | Viscera | 1 | 2005 | 13 | 0.060 |
Why?
| | Mitosis | 1 | 2006 | 164 | 0.060 |
Why?
| | Pregnancy, Multiple | 1 | 2005 | 14 | 0.060 |
Why?
| | Knee Joint | 1 | 2008 | 325 | 0.060 |
Why?
| | Remission, Spontaneous | 1 | 2005 | 37 | 0.060 |
Why?
| | Radiography | 1 | 2008 | 828 | 0.060 |
Why?
| | Iron | 1 | 2006 | 235 | 0.060 |
Why?
| | Rare Diseases | 1 | 2005 | 89 | 0.060 |
Why?
| | Foot | 1 | 2005 | 104 | 0.060 |
Why?
| | Pregnancy Trimester, Third | 1 | 2005 | 78 | 0.060 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2007 | 192 | 0.060 |
Why?
| | Infant, Newborn | 2 | 2007 | 5061 | 0.060 |
Why?
| | Treponema pallidum | 1 | 2004 | 7 | 0.060 |
Why?
| | Infant | 2 | 2008 | 7979 | 0.060 |
Why?
| | Renal Insufficiency | 1 | 2006 | 137 | 0.060 |
Why?
| | Infliximab | 1 | 2005 | 94 | 0.060 |
Why?
| | Urticaria | 1 | 2005 | 51 | 0.060 |
Why?
| | Hand | 1 | 2005 | 134 | 0.060 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2007 | 314 | 0.060 |
Why?
| | Sclerosis | 1 | 2004 | 11 | 0.060 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2009 | 488 | 0.060 |
Why?
| | Glucocorticoids | 2 | 2012 | 552 | 0.060 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2020 | 1147 | 0.060 |
Why?
| | Kidney Transplantation | 1 | 2010 | 558 | 0.060 |
Why?
| | Infusions, Intravenous | 1 | 2005 | 374 | 0.060 |
Why?
| | Nails | 1 | 2003 | 9 | 0.060 |
Why?
| | Staining and Labeling | 1 | 2004 | 139 | 0.060 |
Why?
| | Twins | 1 | 2005 | 240 | 0.060 |
Why?
| | Cell Nucleus | 1 | 2006 | 553 | 0.060 |
Why?
| | Quality of Health Care | 1 | 2008 | 576 | 0.060 |
Why?
| | Chest Pain | 1 | 2004 | 82 | 0.060 |
Why?
| | Cell Cycle Proteins | 1 | 2007 | 553 | 0.050 |
Why?
| | Arm | 1 | 2003 | 105 | 0.050 |
Why?
| | Plant Leaves | 1 | 2003 | 112 | 0.050 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2006 | 449 | 0.050 |
Why?
| | Atrophy | 1 | 2003 | 152 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2003 | 286 | 0.050 |
Why?
| | Young Adult | 2 | 2015 | 10518 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 795 | 0.050 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2004 | 221 | 0.050 |
Why?
| | Adrenal Cortex Hormones | 1 | 2005 | 509 | 0.050 |
Why?
| | Blotting, Western | 1 | 2004 | 1153 | 0.050 |
Why?
| | Coronary Disease | 1 | 2004 | 348 | 0.050 |
Why?
| | Plasma Cells | 1 | 2021 | 57 | 0.050 |
Why?
| | Age Factors | 1 | 2008 | 2911 | 0.050 |
Why?
| | Neoplasm Staging | 1 | 2004 | 1178 | 0.050 |
Why?
| | Cohort Studies | 2 | 2008 | 4949 | 0.050 |
Why?
| | Osteoporosis | 1 | 2003 | 227 | 0.040 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 1361 | 0.040 |
Why?
| | Rats, Wistar | 2 | 2012 | 368 | 0.040 |
Why?
| | Kidney | 1 | 2007 | 1207 | 0.040 |
Why?
| | Respiratory Insufficiency | 1 | 2003 | 292 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 1 | 2007 | 2129 | 0.040 |
Why?
| | Genotype | 1 | 2003 | 1787 | 0.040 |
Why?
| | Risk Factors | 2 | 2009 | 8702 | 0.040 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2006 | 963 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 930 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2019 | 178 | 0.040 |
Why?
| | Mice, Nude | 1 | 2019 | 639 | 0.040 |
Why?
| | Clinical Competence | 1 | 2003 | 912 | 0.040 |
Why?
| | Arthritis, Rheumatoid | 1 | 2005 | 1003 | 0.030 |
Why?
| | Early Detection of Cancer | 1 | 2020 | 340 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 273 | 0.030 |
Why?
| | Minoxidil | 1 | 2013 | 1 | 0.030 |
Why?
| | Retinoids | 1 | 2013 | 31 | 0.030 |
Why?
| | Acne Vulgaris | 1 | 2013 | 20 | 0.030 |
Why?
| | Inflammation | 1 | 2004 | 2500 | 0.030 |
Why?
| | Lung Neoplasms | 1 | 2006 | 2207 | 0.030 |
Why?
| | Hydroxychloroquine | 1 | 2013 | 55 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2003 | 4448 | 0.030 |
Why?
| | Emergency Service, Hospital | 1 | 2004 | 1829 | 0.030 |
Why?
| | Rats | 2 | 2012 | 5033 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 2751 | 0.030 |
Why?
| | Disease Progression | 1 | 2019 | 2423 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2003 | 4669 | 0.020 |
Why?
| | Transcriptome | 1 | 2017 | 736 | 0.020 |
Why?
| | Injections, Intradermal | 1 | 2011 | 12 | 0.020 |
Why?
| | Cosmetic Techniques | 1 | 2011 | 11 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 2011 | 409 | 0.020 |
Why?
| | Epoetin Alfa | 1 | 2009 | 6 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2012 | 962 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2009 | 204 | 0.020 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2009 | 42 | 0.020 |
Why?
| | Drug Synergism | 1 | 2009 | 317 | 0.020 |
Why?
| | Keratin-15 | 1 | 2007 | 12 | 0.020 |
Why?
| | Remission Induction | 1 | 2008 | 240 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2009 | 1088 | 0.020 |
Why?
| | Axilla | 1 | 2006 | 39 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2009 | 1243 | 0.020 |
Why?
| | Databases, Factual | 1 | 2010 | 1139 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2009 | 1870 | 0.020 |
Why?
| | Silver Staining | 1 | 2004 | 17 | 0.020 |
Why?
| | Echocardiography, Stress | 1 | 2004 | 20 | 0.010 |
Why?
| | Incidence | 1 | 2010 | 2335 | 0.010 |
Why?
| | Calcium | 1 | 2009 | 1103 | 0.010 |
Why?
| | Causality | 1 | 2004 | 106 | 0.010 |
Why?
| | Mice | 1 | 2019 | 15052 | 0.010 |
Why?
| | Gastrointestinal Diseases | 1 | 2004 | 184 | 0.010 |
Why?
| | Electroencephalography | 1 | 2004 | 365 | 0.010 |
Why?
| | Exercise Test | 1 | 2004 | 539 | 0.010 |
Why?
| | Acute Disease | 1 | 2004 | 914 | 0.010 |
Why?
| | Recurrence | 1 | 2004 | 953 | 0.010 |
Why?
| | Survival Analysis | 1 | 2004 | 1219 | 0.010 |
Why?
| | Hospitalization | 1 | 2004 | 1765 | 0.010 |
Why?
|
|
High's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|